etravirine (TMC-125)

04/16/2012 - "In highly treatment-experienced patients with HIV-1 infection and evidence of viral replication, the addition of etravirine to an OBT regimen provides an effective and well tolerated treatment that leads to improvements in both virological and immunological outcomes."
10/01/2008 - "Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb dose-ranging study involving treatment-experienced patients with HIV-1 infection."
01/01/2010 - "Effects of etravirine versus placebo on health-related quality of life in treatment-experienced HIV patients as measured by the functional assessment of human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials."
03/01/2013 - "Does once-daily etravirine have a role in the management of HIV-1 infection?"
10/01/2012 - "Etravirine: a guide to its use in treatment-experienced pediatric patients with HIV-1 infection in the US."

01/01/2006 - "Phase IIa clinical trials of etravirine for the treatment of HIV infections, initiated in November 2001, have been completed. "
01/01/2010 - "Profile of etravirine for the treatment of HIV infection."
08/01/2008 - "Etravirine for the treatment of HIV infection."
08/01/2014 - "Etravirine is a non-nucleoside reverse transcriptase inhibitor used in combination with other antiretrovirals for the treatment of HIV infection. "
12/01/2009 - "Etravirine (ETR) is the first representative of a new generation of non-nucleoside reverse transcriptase inhibitors (NNRTI) and is indicated in patients with HIV infection and virological failure. "

03/15/2009 - "Efficacy of etravirine for treatment of acute HIV meningoencephalitis."
03/15/2009 - "Etravirine has a satisfactory safety profile and, in this case, was a durable alternative therapy for HIV meningoencephalitis."

10/01/2010 - "Etravirine has demonstrated a favorable safety and tolerability profile; the incidence of treatment-emergent adverse events was comparable with placebo in the DUET trials, with the exception of rash. "
12/01/2008 - "In the DUET studies, etravirine demonstrated virological efficacy superior to the control arms with comparable rates of adverse events with the exception of rash. "
08/01/2012 - "The frequency of AEs of interest was generally similar between the treatment groups, both overall and when adjusted for treatment exposure, with the exception of rash which was more frequent in the etravirine group."
08/01/2012 - "However, a significant difference in the frequency of rash was observed (20.5% vs. 11.8%, respectively; P < 0.0001); rash was generally mild to moderate in severity; the rate of discontinuation because of rash was low (2.2% vs. 0% in the etravirine and placebo groups, respectively). "
04/16/2012 - "The only treatment-emergent adverse event that occurred with a higher frequency for recipients of etravirine compared with placebo plus OBT was rash. "

06/01/2013 - "Etravirine for the treatment of HIV/AIDS."
06/01/2010 - "DUET demonstrated superior outcomes in virologic suppression (plasma viral load < 50 copies/ml) and clinical end points including new AIDS-defining illnesses and death, in those randomized to receive etravirine. "
01/01/2010 - "In addition, patients on the etravirine arm had fewer AIDS-defining conditions, hospitalizations, and lower mortality compared with the OBR control arm."
11/13/2009 - "Significantly fewer patients in the etravirine group experienced at least one confirmed or probable AIDS-defining illness/death (6 vs. 10%; P = 0.0408). "
10/01/2010 - "Clinical studies demonstrated that etravirine in combination with other antiretrovirals achieved superior levels of undetectable plasma HIV RNA and CD4 cell count increases that led to reductions in risk of death and development of AIDS-defining illnesses when compared with placebo. "